These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 19318477)

  • 41. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion.
    Zorn E; Hercend T
    Eur J Immunol; 1999 Feb; 29(2):602-7. PubMed ID: 10064076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.
    Libon F; Arrese JE; Rorive A; Nikkels AF
    Clin Exp Dermatol; 2013 Apr; 38(3):276-9. PubMed ID: 23020081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Phan GQ; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; Duray PH; Steinberg SM; Allison JP; Davis TA; Rosenberg SA
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8372-7. PubMed ID: 12826605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.
    Wistuba-Hamprecht K; Martens A; Heubach F; Romano E; Geukes Foppen M; Yuan J; Postow M; Wong P; Mallardo D; Schilling B; Di Giacomo AM; Khammari A; Dreno B; Maio M; Schadendorf D; Ascierto PA; Wolchok JD; Blank CU; Garbe C; Pawelec G; Weide B
    Eur J Cancer; 2017 Mar; 73():61-70. PubMed ID: 28167454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
    Liénard D; Rimoldi D; Marchand M; Dietrich PY; van Baren N; Geldhof C; Batard P; Guillaume P; Ayyoub M; Pittet MJ; Zippelius A; Fleischhauer K; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2004 May; 4():4. PubMed ID: 15149168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
    Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
    Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma.
    Meidenbauer N; Zippelius A; Pittet MJ; Laumer M; Vogl S; Heymann J; Rehli M; Seliger B; Schwarz S; Le Gal FA; Dietrich PY; Andreesen R; Romero P; Mackensen A
    Cancer Res; 2004 Sep; 64(17):6319-26. PubMed ID: 15342421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The proportion of circulating CD45RO
    Tietze JK; Angelova D; Heppt MV; Reinholz M; Murphy WJ; Spannagl M; Ruzicka T; Berking C
    Eur J Cancer; 2017 Apr; 75():268-279. PubMed ID: 28242504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
    Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S
    J Immunother; 2015; 38(2):80-4. PubMed ID: 25658618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
    J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
    Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
    Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
    Ascierto PA
    Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop a novel anti-cancer vaccine.
    Saleh F; Renno W; Klepacek I; Ibrahim G; Dashti H; Asfar S; Behbehani A; Al-Sayer H; Dashti A
    Curr Pharm Des; 2005; 11(27):3531-43. PubMed ID: 16248806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An immune-active tumor microenvironment favors clinical response to ipilimumab.
    Ji RR; Chasalow SD; Wang L; Hamid O; Schmidt H; Cogswell J; Alaparthy S; Berman D; Jure-Kunkel M; Siemers NO; Jackson JR; Shahabi V
    Cancer Immunol Immunother; 2012 Jul; 61(7):1019-31. PubMed ID: 22146893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.
    Postow MA; Yuan J; Kitano S; Lesokhin AM; Wolchok JD
    Methods Mol Biol; 2014; 1102():83-95. PubMed ID: 24258975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Lotem M; Merims S; Frank S; Ospovat I; Peretz T
    Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.